The inquiry centers on events surrounding August 13, 2026, when Cellebrite reported its second-quarter performance. The company disclosed that its Annual Recurring Revenue failed to meet the lower threshold of previously issued guidance, prompting a downward revision for its full-year projections. Compounding market concerns, the firm simultaneously announced the abrupt exit of CEO Tom Hogan.

Investors reacted sharply to the disclosures, driving Cellebrite’s share price down by $4.45 to close at $10.80. Pomerantz LLP, a firm specializing in securities class action litigation, is now seeking to determine if these financial discrepancies and management shifts constitute securities fraud or a breach of fiduciary duty. Shareholders affected by the decline are being encouraged to contact Danielle Peyton at the firm to discuss potential involvement in a class action suit.